Compare VanEck Semiconductor ETF (SMH) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Twist Bioscience Corp — how do they compare? VanEck Semiconductor ETF trades at $588, while Twist Bioscience Corp trades at $124.27 (market cap $7.72B). The key difference: Twist Bioscience Corp is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| SMH | TWST | |
|---|---|---|
52-Week High | $668.91 | $124.88 |
52-Week Low | $286.43 | $24.16 |
Market Cap | — | $7.72B |
Sector | — | Health |
Enterprise Value | — | $7.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH, the VanEck Semiconductor ETF, trades at $588.7, up 3.39% ($19.29) in the last session, with a bullish technical signal driven by moving averages. The ETF holds major semiconductor stocks but lacks disclosed financial ratios. Recent news highlights institutional buying, such as Ferguson Shapiro's $4.53 million investment (SEC filing, August 10, 2026), and mixed sentiment from analysts, including a downgrade to Hold by Seeking Alpha (August 10, 2026).
Outlook is cautiously optimistic, supported by AI-driven demand and global semiconductor initiatives, like South Korea's $3.52 billion fund (Reuters, August 10, 2026). Risks include tariff impacts from Trump's polysilicon policy and volatility from concentrated holdings. Investors should weigh growth potential against sector-specific headwinds.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
